1, what's the effect?
Yujie (gemcitabine hydrochloride for injection) has broad-spectrum anti-tumor activity, and can be used to treat solid tumors such as pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer and so on, with remarkable curative effect. It inhibits tumor replication by inhibiting dna connection and blocks dna repair by covering the end of peptide chain, which has achieved great success in the treatment of non-small cell lung cancer and pancreatic cancer.
Yujie (gemcitabine hydrochloride for injection) is a newly synthesized difluornucleoside antimetabolite antineoplastic agent, which is mainly used to treat locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic pancreatic cancer. Yujie (gemcitabine hydrochloride for injection) can also enhance its anti-cytotoxicity ability, and clinical research shows that it has remarkable curative effect on many tumors. The recommended dose for adults is 1000mg/m2 intravenous drip for 30 minutes, once a week for three weeks, then rest for one week and repeat every four weeks. Reduce the dose according to the patient's toxic reaction.
Yujie (gemcitabine hydrochloride for injection) is rapidly distributed in various tissues in the body after intravenous injection. The longer the infusion time, the wider and deeper the distribution volume and the longer the half-life. The t 1/2 of this product is about 32 ~ 94min； after a short time of infusion. Within 5 minutes after the end of infusion, the peak blood concentration of this product was 3.2 ~ 45.5 μ g/ml; Only a few of this product combine with protein, which can be rapidly and completely metabolized by cytidine in liver, kidney, blood and other tissues, and less than10% of the original drugs and metabolites are excreted in urine; The total clearance rate was 29.2 ~ 92.2 L/(h m2), which was related to sex and age (individual difference was 52.2%). Yujie (gemcitabine hydrochloride for injection) has shown remarkable efficacy in improving tumor-related symptoms and greatly improved the quality of life of patients with advanced pancreatic cancer.
Step 2 explain
Gemcitabine hydrochloride.
Dosage form:
inject
Shape:
White loose mass.
Function indication:
It is suitable for the treatment of advanced non-small cell lung cancer.
Specifications/Chinese and Western medicines:
1g
Usage and dosage:
The recommended dose of gemcitabine for adults is 1000mg/m2, once a week for three weeks, then rest for one week and repeat every four weeks. Reduce the dose according to the patient's toxic reaction. Preparation method: Each bottle (containing 200mg of gemcitabine) should be injected with at least 5 ml of 0.9% sodium chloride injection (containing less than 40 mg/ml of gemcitabine) and shaken to dissolve. The dosage required for administration can be further diluted with 0.9% sodium chloride injection. The prepared gemcitabine solution should be stored at room temperature and used within 24 hours. The gemcitabine solution should not be refrigerated to prevent crystallization. Elderly patients: elderly patients over 65 years old can also tolerate it well. Although age affects the clearance rate and half-life of gemcitabine, there is no evidence that elderly patients need to adjust their doses. Children: The use of gemcitabine by children has not been studied.
Adverse reactions:
Hematological system: Because gemcitabine has bone marrow inhibitory effect, anemia, leukopenia and thrombocytopenia may occur after gemcitabine application. Bone marrow suppression is often mild to moderate, mostly neutropenia. Thrombocytopenia is also common. Digestive system: about 2/3 patients have abnormal liver transaminase, but most of them are mild and non-progressive, so there is no need to stop taking drugs. Patients with impaired liver function should be especially cautious when using gemcitabine (see dosage and usage). It is reported that about13 patients have nausea and vomiting reaction, and 20% patients need drug treatment. This drug is rarely dose-limiting toxicity and can be easily controlled by anti-vomiting drugs. Kidney: Nearly half of patients may have mild proteinuria and hematuria after taking the medicine, but rarely accompanied by clinical symptoms and changes in serum creatinine and urea nitrogen. However, it is reported that some cases have renal failure of unknown cause. Therefore, for patients with renal insufficiency, gemcitabine should be used with special caution (see dosage and usage). Allergy: About 25% patients may have a rash, and 10% patients may have itching. Usually, the rash is mild, with non-dose limiting toxicity and effective local treatment, and peeling, blisters and ulcers are rarely reported. During the infusion of gemcitabine, less than 1% of patients may have bronchospasm, which is generally mild and short-lasting, but may require parenteral administration. Patients who are known to be highly sensitive to this drug should not use this drug (see contraindications). It is reported that about 10% of patients have difficulty breathing within a few hours after taking the medicine. This kind of dyspnea often lasts for a short time and has mild symptoms. It rarely requires dosage adjustment, and most of them do not require special treatment. Its pathogenesis and relationship with gemcitabine are not clear.